Materna Medical, a women’s pelvic health platform company, has closed a $5 million B3 financing round led by InnovaHealth Partners, Wavemaker360 Health, and Band of Angels with continued support from existing investors.
The funding will support completion of the EASE pivotal trial readout – a large randomized controlled trial across 20 U.S. hospitals evaluating the Ellora Obstetrical System – alongside commercial manufacturing buildout and launch preparations. Ellora is an investigational device designed to reduce pelvic floor muscle injury during vaginal delivery in first-time mothers. A first-in-class reimbursement code for the device is now active.
“We are thrilled to be entering this next phase as we prepare for the Ellora launch, bringing an important innovation to women’s health,” said president and CEO Tracy MacNeal.
Materna’s first product, Milli, is an FDA-cleared vaginal dilator for vaginismus and related painful sex, available over the counter since 2023. The Ellora launch would expand the company’s platform from treating pelvic floor conditions after they occur to preventing injury during delivery – a shift from reactive to preventive pelvic health.
Pelvic floor injury during childbirth affects a significant proportion of first-time mothers and contributes to long-term incontinence, prolapse, and sexual dysfunction.
